Fewer than 10% of people who could benefit from obesity jabs like Wegovy can access them, warns the World Health Organization as it publishes its initial guidance on the medications.
Considering more than one billion people worldwide now living with obesity, it is urging more widespread and fairer availability to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The latest guidance affirms that obesity is a long-term condition that can be managed with holistic and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant barriers to universal availability to the jabs that can help people shift substantial weight, says the body.
Weight-Loss Drug Scarcity
Despite the current best projected case, the manufacturing of such drugs could only cover about 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation calls on nations and manufacturers to increase access, via approaches like voluntary licensing.
The intellectual property rights on semaglutide – the main ingredient of a leading brand – is due to expire in several nations in 2026.
The Way Obesity Injections Work
GLP-1 drugs mimick a natural hormone to delay gastric emptying, suppress the appetite and enhance the sense of being full so users eat less.
People typically start to lose weight after several weeks of starting on the once-weekly jabs.
Studies points to users may regain a significant portion a year later of halting the treatment, because their normal hunger come back.
To be carrying excess weight elevates your chance for developing medical conditions, including type 2 diabetes, heart disease, brain attack, and certain malignancies.
Excess weight impacts people in every country and was associated with millions of deaths worldwide in 2024, as per the health agency.
